Evogene posts Q3 2025 results, adds GAAP tables to F-3, S-8

Rhea-AI Filing Summary

Evogene Ltd. submitted a Form 6-K announcing that it has released its financial results for the third quarter ended September 30, 2025. The company also scheduled a conference call on November 20, 2025 to discuss these quarterly results and made an investor slide presentation available.

The third quarter 2025 financial results are provided in a press release attached as Exhibit 99.1, and the accompanying slide deck is attached as Exhibit 99.2. The GAAP financial statement tables in the press release are incorporated by reference into Evogene’s existing registration statements on Form F-3 and multiple Form S-8 filings, so they now form part of those registration materials from the date of this Form 6-K.

UNITED STATES

 SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 OF

THE SECURITIES EXCHANGE ACT OF 1934

For the month of November 2025

Commission File Number: 001-36187

EVOGENE LTD.

  (Translation of Registrant’s Name into English)

13 Gad Feinstein Street, Park Rehovot, Rehovot 7638517, Israel

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒       Form 40-F ☐

CONTENTS

On November 20, 2025, Evogene Ltd. (“Evogene”) announced its financial results for the third quarter ended September 30, 2025.  A Copy of the press release announcing those results is furnished as Exhibit 99.1 to this Report of Foreign Private Issuer on Form 6-K (this “Form 6-K”) and is incorporated herein by reference.

Evogene is holding a conference call on November 20, 2025 to discuss its quarterly results for the quarter ended September 30, 2025 and, in connection with that call, will make available to its investors a slide presentation to provide additional information regarding its business and its financial results. That slide presentation is attached as Exhibit 99.2 to this Form 6-K and is incorporated herein by reference.

The GAAP financial statements tables contained in the press release attached to this Form 6-K are incorporated by reference in the registration statements on Form F-3 (Securities and Exchange Commission (“SEC”) File No. 333-277565), and Form S-8 (SEC File Nos. 333-259215, 333-193788, 333-201443, 333-203856, 333-286197 and 333-286197) of Evogene, and will be a part thereof from the date on which this Form 6-K is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.

 

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: November 20, 2025 EVOGENE LTD.
(Registrant)

By: /s/ Yaron Eldad
Yaron Eldad
Chief Financial Officer

EXHIBIT INDEX

EXHIBIT NO.		DESCRIPTION
99.1		Press Release: Evogene Reports Third Quarter 2025 Financial Results.
99.2		Slide presentation for conference call of Evogene held on November 20, 2025, discussing Evogene’s quarterly financial results for the third quarter of 2025.

FAQ

What did Evogene Ltd. (EVGN) announce in its November 2025 Form 6-K?

Evogene Ltd. announced that it has released its financial results for the third quarter ended September 30, 2025, furnished as a press release attached as Exhibit 99.1.

Does Evogene (EVGN) provide a presentation for its Q3 2025 results?

Yes. Evogene is holding a conference call on November 20, 2025 to discuss its Q3 2025 results and has made an investor slide presentation available as Exhibit 99.2.

How are Evogene’s Q3 2025 GAAP financial statements used in its SEC registrations?

The GAAP financial statements tables in the Q3 2025 press release are incorporated by reference into Evogene’s Form F-3 (File No. 333-277565) and multiple Form S-8 registration statements.

Which exhibits are included with Evogene’s Q3 2025 Form 6-K?

The Form 6-K includes Exhibit 99.1, a press release titled "Evogene Reports Third Quarter 2025 Financial Results," and Exhibit 99.2, a slide presentation for the November 20, 2025 conference call.

Does the Evogene (EVGN) Form 6-K itself contain detailed Q3 2025 financial figures?

The Form 6-K text summarizes that Evogene released its third quarter 2025 financial results; the detailed GAAP tables are contained in the attached press release (Exhibit 99.1) and incorporated by reference.

What period do Evogene’s newly reported results in this Form 6-K cover?

The financial results referenced in this Form 6-K cover the third quarter ended September 30, 2025.